Clinic
San Jacinto Methodist Hospital
San Jacinto Methodist Hospital was paid $27.82M by Medicaid between Jan 2020 and Dec 2024, across 103 billing codes. Its largest line is 99284, emergency room visit (serious) — 63% of everything it billed.
33Billing provider infoSAN JACINTO METHODIST HOSPITAL
BAYTOWN, TX 77521
BAYTOWN, TX 77521
33aNPI1891789772assigned 09/07/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$27.82M
24GClaims226,371
24DCodes billed103
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#17 of 320
Median peer was paid$205K
This provider vs. median136×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 6,515 | $1.02M | |
| 2021 | 58,073 | $6.25M | |
| 2022 | 74,431 | $8.21M | |
| 2023 | 60,269 | $9.15M | |
| 2024incomplete | 27,083 | $3.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 63% | 18,913 | 18,202 | $17.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 6,339 | 5,997 | $5.18M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.7% | 10,090 | 9,721 | $1.86M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 5,662 | 5,127 | $611K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 501 | 497 | $257K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13,144 | 12,668 | $217K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,130 | 2,945 | $203K |
| 80053 | Comprehensive metabolic panel | <1% | 17,762 | 15,987 | $187K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,267 | 1,222 | $171K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 10,353 | 10,154 | $141K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,787 | 18,068 | $135K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 823 | 787 | $127K |
91 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,001 | $126K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,566 | $114K |
| 84703 | <1% | 8,367 | $55K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 996 | $54K |
| 87088 | <1% | 7,211 | $52K | |
| 76801 | <1% | 611 | $51K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,276 | $46K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,628 | $44K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,235 | $44K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 581 | $44K |
| 81001 | <1% | 12,579 | $41K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,128 | $37K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 437 | $32K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 996 | $28K |
| 83880 | <1% | 1,895 | $28K | |
| 84484 | <1% | 4,155 | $25K | |
| 87070 | <1% | 2,693 | $19K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 194 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,237 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,240 | $13K |
| 83690 | <1% | 3,154 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,752 | $13K |
| 84702 | <1% | 1,075 | $12K | |
| G0378 | Hospital observation service, per hour | <1% | 223 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,206 | $9K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,079 | $8K |
| 76830 | Ultrasound, transvaginal | <1% | 88 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,279 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 204 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 78 | $7K |
| 86900 | <1% | 590 | $6K | |
| 83605 | <1% | 1,357 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,419 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 213 | $6K |
| 86901 | <1% | 1,290 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,255 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 661 | $5K |
| 82805 | <1% | 177 | $5K | |
| 83735 | <1% | 1,578 | $4K | |
| 87400 | <1% | 288 | $4K | |
| 85730 | <1% | 1,503 | $4K | |
| 85610 | <1% | 1,749 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,213 | $3K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 33 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 93 | $3K |
| 87077 | <1% | 913 | $3K | |
| 87040 | <1% | 545 | $3K | |
| 85027 | <1% | 638 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 611 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 93 | $2K |
| 86850 | <1% | 188 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 26 | $2K |
| 87186 | <1% | 655 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 474 | $1K |
| 80061 | Lipid panel | <1% | 317 | $1K |
| CP007 | <1% | 26 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $1K |
| 80076 | <1% | 293 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $977.85 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $917.82 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 627 | $906.21 |
| 86769 | <1% | 51 | $838.82 | |
| 84100 | <1% | 478 | $789.05 | |
| 82550 | <1% | 300 | $723.52 | |
| 0100U | <1% | 12 | $711.12 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 31 | $685.70 |
| CP008 | <1% | 14 | $665.23 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 18 | $608.62 |
| 82077 | <1% | 94 | $604.72 | |
| 87340 | <1% | 12 | $566.39 | |
| 87420 | <1% | 32 | $528.61 | |
| 84439 | <1% | 144 | $423.00 | |
| 85007 | <1% | 148 | $419.05 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 71 | $395.45 |
| 86780 | <1% | 12 | $330.84 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $328.58 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 368 | $304.80 |
| 74018 | <1% | 13 | $290.24 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 172 | $189.41 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 32 | $179.56 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 94 | $134.78 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 24 | $76.59 |
| 87210 | <1% | 14 | $54.13 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 688 | $43.19 |
| 80299 | <1% | 16 | $14.88 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 14 | $3.33 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 26 | $2.80 |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 0% | 249 | $0.00 |
| 96376 | 0% | 327 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 91 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBERNARD, DAVID (CEO)